加强难愈合创面间充质干细胞治疗的基础与转化研究

史春梦

doi:10.3760/cma.j.cn501225-20220913-00405

加强难愈合创面间充质干细胞治疗的基础与转化研究

doi: 10.3760/cma.j.cn501225-20220913-00405

史春梦

陆军军医大学火箭军医学教研室，创伤、烧伤与复合伤国家重点实验室，重庆　　400038

基金项目:

国家自然科学基金重点项目 82030056

计量
- 文章访问数: 1300
- HTML全文浏览量: 104
- PDF下载量: 53
- 被引次数: 0
出版历程
- 收稿日期: 2022-09-13

To strengthen the basic and translational research of mesenchymal stem cell-based therapy for refractory wounds

Shi Chunmeng

Institute of Rocket Force Medicine, State Key Laboratory of Trauma, Burns and Combined Injury, Army Medical University, Chongqing 400038, China

Funds:

Key Program of National Natural Science Foundation of China 82030056

摘要

摘要: 近年来，细胞疗法在难愈合创面修复领域的应用显示出广阔前景，其中间充质干细胞是最受关注和研究最为广泛的细胞类型。尽管临床转化研究已取得快速发展，但细胞疗法效果并不稳定，多数临床试验尚未取得预想结果。深入研究表明，异质性是制约细胞疗法深入开展和亟待研究的重要问题。该文基于间充质干细胞的研究进展，探讨难愈合创面细胞治疗策略的现状和挑战。
- 间充质干细胞 /
- 细胞和组织疗法 /
- 转化医学研究 /
- 难愈合创面 /
- 创面修复 /
- 异质性
Abstract: In recent years, the application of cell-based therapy in the field of refractory wound repair has shown broad prospects, among which the mesenchymal stem cell is the most concerned and widely studied cell type. Despite the rapid development of clinical translational research, the therapeutic effect of cell-based therapy is not consistent, and most clinical trials have not achieved the desired results. Further studies have found that heterogeneity is an important issue that restricts the further development of cell-based therapy and urgently needs to be studied. Based on the research progress of mesenchymal stem cells, in the review, we discuss the current status and challenges of cell-based therapy strategies for refractory wounds.
- Mesenchymal stem cells /
- Cell- and tissue-based therapy /
- Translational medical research /
- Refractory wounds /
- Wound repair /
- Heterogeneity
作者声明不存在利益冲突

HTML全文

参考文献(42)

[1]	Otero-ViñasM,FalangaV.Mesenchymal stem cells in chronic wounds: the spectrum from basic to advanced therapy[J].Adv Wound Care (New Rochelle),2016,5(4):149-163.DOI: 10.1089/wound.2015.0627.
[2]	MargianaR,MarkovA,ZekiyAO,et al.Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review[J].Stem Cell Res Ther,2022,13(1):366.DOI: 10.1186/s13287-022-03054-0.
[3]	HoangDM,PhamPT,BachTQ,et al.Stem cell-based therapy for human diseases[J].Signal Transduct Target Ther,2022,7(1):272.DOI: 10.1038/s41392-022-01134-4.
[4]	MendicinoM,BaileyAM,WonnacottK,et al.MSC-based product characterization for clinical trials: an FDA perspective[J].Cell Stem Cell,2014,14(2):141-145.DOI: 10.1016/j.stem.2014.01.013.
[5]	RennerfeldtDA,Van VlietKJ.Concise review: when colonies are not clones: evidence and implications of intracolony heterogeneity in mesenchymal stem cells[J].Stem Cells,2016,34(5):1135-1141.DOI: 10.1002/stem.2296.
[6]	SippD,RobeyPG,TurnerL.Clear up this stem-cell mess[J].Nature,2018,561(7724):455-457.DOI: 10.1038/d41586-018-06756-9.
[7]	CaplanAI.Mesenchymal stem cells: time to change the name![J].Stem Cells Transl Med,2017,6(6):1445-1451.DOI: 10.1002/sctm.17-0051.
[8]	DominiciM,Le BlancK,MuellerI,et al.Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement[J].Cytotherapy,2006,8(4):315-317.DOI: 10.1080/14653240600855905.
[9]	YessentayevaSY,OrakbayLZ,AdilhanovaA,et al.Approaches to the use of stem cells in regenerative medicine[J].Anal Biochem,2022,645:114608.DOI: 10.1016/j.ab.2022.114608.
[10]	JiangB,YanL,WangX,et al.Concise review: mesenchymal stem cells derived from human pluripotent cells, an unlimited and quality-controllable source for therapeutic applications[J].Stem Cells,2019,37(5):572-581.DOI: 10.1002/stem.2964.
[11]	XieZ,YuW,YeG,et al.Single-cell RNA sequencing analysis of human bone-marrow-derived mesenchymal stem cells and functional subpopulation identification[J].Exp Mol Med,2022,54(4):483-492.DOI: 10.1038/s12276-022-00749-5.
[12]	ZhangC,HanX,LiuJ,et al.Single-cell transcriptomic analysis reveals the cellular heterogeneity of mesenchymal stem cells[J].Genomics Proteomics Bioinformatics,2022,20(1):70-86.DOI: 10.1016/j.gpb.2022.01.005.
[13]	ChenZ,WangY,ShiC.Therapeutic implications of newly identified stem cell populations from the skin dermis[J].Cell Transplant,2015,24(8):1405-1422.DOI: 10.3727/096368914X682431.
[14]	ShiC,ChengT,SuY,et al.Effects of dermal multipotent cell transplantation on skin wound healing[J].J Surg Res,2004,121(1):13-19.DOI: 10.1016/j.jss.2004.04.008.
[15]	LynchMD,WattFM.Fibroblast heterogeneity: implications for human disease[J].J Clin Invest,2018,128(1):26-35.DOI: 10.1172/JCI93555.
[16]	ChenY,ZhangZ,YangX,et al.Odontogenic MSC heterogeneity: challenges and opportunities for regenerative medicine[J].Front Physiol,2022,13:827470.DOI: 10.3389/fphys.2022.827470.
[17]	张喻平,张琼,邓芳,等.高糖微环境下P62对人表皮细胞株HaCaT迁移和运动性的影响及其机制[J].中华烧伤与创面修复杂志,2022,38(11):1014-1022.DOI: 10.3760/cma.j.cn501225-20220630-00272.
[18]	KaiserM,Rodriguez-MenocalL,BadiavasEV.Role of extracellular vesicles in stem cell therapy[J/OL].Curr Stem Cell Res Ther,2022(2022-06-30)[2020-09-13]. https://pubmed.ncbi.nlm.nih.gov/35786194/.DOI:10.2174/1574888X17666220630162836.[published online ahead of print].
[19]	HadeMD,SuireCN,MossellJ,et al.Extracellular vesicles: emerging frontiers in wound healing[J].Med Res Rev,2022,42(6):2102-2125.DOI: 10.1002/med.21918.
[20]	BianD,WuY,SongG,et al.The application of mesenchymal stromal cells (MSCs) and their derivative exosome in skin wound healing: a comprehensive review[J].Stem Cell Res Ther,2022,13(1):24.DOI: 10.1186/s13287-021-02697-9.
[21]	BikorimanaJP,AbusarahJ,SalameN,et al.Humoral immunity to allogeneic immunoproteasome-expressing mesenchymal stromal cells requires efferocytosis by endogenous phagocytes[J].Cells,2022,11(4):596.DOI: 10.3390/cells11040596.
[22]	HuangY,WuQ,TamPKH.Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications[J].Int J Mol Sci,2022,23(17):10023.DOI: 10.3390/ijms231710023.
[23]	Sid-OtmaneC,PerraultLP,LyHQ.Mesenchymal stem cell mediates cardiac repair through autocrine, paracrine and endocrine axes[J].J Transl Med,2020,18(1):336.DOI: 10.1186/s12967-020-02504-8.
[24]	易佳荣,李泽楠,谢慧清,等.人脐静脉内皮细胞外泌体对糖尿病兔创面愈合的作用及其机制[J].中华烧伤与创面修复杂志,2022,38(11):1023-1033.DOI: 10.3760/cma.j.cn501225-20220622-00254.
[25]	曹涛,肖丹,计鹏,等. 肝细胞生长因子修饰的人脂肪间充质干细胞外泌体对糖尿病小鼠全层皮肤缺损的作用[J].中华烧伤与创面修复杂志,2022,38(11):1004-1013.DOI: 10.3760/cma.j.cn501225-20220731-00330.
[26]	ZuoR,LiuM,WangY,et al.BM-MSC-derived exosomes alleviate radiation-induced bone loss by restoring the function of recipient BM-MSCs and activating Wnt/β-catenin signaling[J].Stem Cell Res Ther,2019,10(1):30.DOI: 10.1186/s13287-018-1121-9.
[27]	YagiH,Soto-GutierrezA,ParekkadanB,et al.Mesenchymal stem cells: mechanisms of immunomodulation and homing[J].Cell Transplant,2010,19(6):667-679.DOI: 10.3727/096368910X508762.
[28]	RangatchewF,Vester-GlowinskiP,RasmussenBS,et al.Mesenchymal stem cell therapy of acute thermal burns: a systematic review of the effect on inflammation and wound healing[J].Burns,2021,47(2):270-294.DOI: 10.1016/j.burns.2020.04.012.
[29]	ZhangC,HuangL,WangX,et al.Topical and intravenous administration of human umbilical cord mesenchymal stem cells in patients with diabetic foot ulcer and peripheral arterial disease: a phase I pilot study with a 3-year follow-up[J].Stem Cell Res Ther,2022,13(1):451.DOI: 10.1186/s13287-022-03143-0.
[30]	BuraA,Planat-BenardV,BourinP,et al.Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia[J].Cytotherapy,2014,16(2):245-257.DOI: 10.1016/j.jcyt.2013.11.011.
[31]	MarinoG,MoraciM,ArmeniaE,et al.Therapy with autologous adipose-derived regenerative cells for the care of chronic ulcer of lower limbs in patients with peripheral arterial disease[J].J Surg Res,2013,185(1):36-44.DOI: 10.1016/j.jss.2013.05.024.
[32]	GaoL,LiuF,TanL,et al.The immunosuppressive properties of non-cultured dermal-derived mesenchymal stromal cells and the control of graft-versus-host disease[J].Biomaterials,2014,35(11):3582-3588.DOI: 10.1016/j.biomaterials.2014.01.008.
[33]	ChenZ,ShenG,TanX,et al.ID1/ID3 mediate the contribution of skin fibroblasts to local nerve regeneration through Itga6 in wound repair[J].Stem Cells Transl Med,2021,10(12):1637-1649.DOI: 10.1002/sctm.21-0093.
[34]	WangX,ChenZ,LuoS,et al.Development of therapeutic small-molecule fluorophore for cell transplantation[J]. Adv Funct Mater,2016,26(46): 8397-8407.DOI: 10.1002/adfm.201600996.
[35]	YuD,ZhangS,MoW,et al.Transplantation of the stromal vascular fraction (SVF) mitigates severe radiation-induced skin injury[J].Radiat Res,2021,196(3):250-260.DOI: 10.1667/RADE-20-00156.1.
[36]	RigottiG,MarchiA,GalièM,et al.Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells[J].Plast Reconstr Surg,2007,119(5):1409-1422.DOI: 10.1097/01.prs.0000256047.47909.71.
[37]	YuanX,LiL,LiuH,et al.Strategies for improving adipose-derived stem cells for tissue regeneration[J/OL].Burns Trauma,2022,10:tkac028[2022-09-13].https://pubmed.ncbi.nlm.nih.gov/35992369/.DOI: 10.1093/burnst/tkac028.
[38]	GentilucciM,MazzocchiM,AlfanoC.Effects of prophylactic lipofilling after radiotherapy compared to non-fat injected breasts: a randomized, objective study[J].Aesthet Surg J,2020,40(10):NP597-NP607.DOI: 10.1093/asj/sjaa182.
[39]	JiangX,YangJ,LiuF,et al.Embryonic stem cell-derived mesenchymal stem cells alleviate skeletal muscle injury induced by acute compartment syndrome[J].Stem Cell Res Ther,2022,13(1):313.DOI: 10.1186/s13287-022-03000-0.
[40]	ElhussienyA,NogamiK,Sakai-TakemuraF,et al.Mesenchymal stem cells derived from human induced pluripotent stem cells improve the engraftment of myogenic cells by secreting urokinase-type plasminogen activator receptor (uPAR)[J].Stem Cell Res Ther,2021,12(1):532.DOI: 10.1186/s13287-021-02594-1.
[41]	SivarajahS,RajGS,MathewsAJ,et al.The generation of GLP-grade human embryonic stem cell banks from four clinical-grade cell lines for preclinical research[J].In Vitro Cell Dev Biol Anim,2010,46(3/4):210-216.DOI: 10.1007/s11626-010-9287-1.
[42]	RouhaniFJ,ZouX,DanecekP,et al.Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells[J].Nat Genet,2022,54(9):1406-1416.DOI: 10.1038/s41588-022-01147-3.